Rastogi

BuildOps Announces New Addition to Its Board of Advisors, CEO of JLL's Work Dynamics Technology, Sharad Rastogi

Retrieved on: 
Tuesday, August 1, 2023
JLL, Rastogi, Dell Technologies, Sharad, Cisco, The Conference Board, Central Waqf Council, Management, Adviser

LOS ANGELES, Aug. 1, 2023 /PRNewswire/ -- BuildOps, the only all-in-one management software built specifically for the modern-day commercial contractor, today announced that Sharad Rastogi, CEO of JLL's Work Dynamics Technology division, is now part of the BuildOps Board of Advisors.

Key Points: 
  • LOS ANGELES, Aug. 1, 2023 /PRNewswire/ -- BuildOps, the only all-in-one management software built specifically for the modern-day commercial contractor, today announced that Sharad Rastogi, CEO of JLL's Work Dynamics Technology division, is now part of the BuildOps Board of Advisors.
  • Rastogi joins the Board at a time when BuildOps is ramping up revenue growth and scaling their business.
  • BuildOps announces latest addition to its Board of Advisors CEO of JLL's Work Dynamics Technology, Sharad Rastogi.
  • "BuildOps has seen such tremendous growth in the last year—especially within the enterprise and private equity space," Said Sharad Rastogi.

Technology implementation is critical to the evolving hybrid workplace

Retrieved on: 
Tuesday, October 11, 2022
Organization, Solution, NYSE, JLL (company), Technology, Research, JLL, Workforce, Rastogi, Marketing, Management

CHICAGO, Oct. 11, 2022 /PRNewswire/ -- As businesses adapt to hybrid work this fall and beyond, JLL's (NYSE: JLL) Technology and Innovation in the Hybrid Age report finds that tech-enabled solutions are crucial to the success of the hybrid work model. The research shows that there is no one-size-fits-all solution and organizations will need to implement tailored tools and processes that work for their employees, clients and business models.   

Key Points: 
  • CHICAGO, Oct. 11, 2022 /PRNewswire/ -- As businesses adapt to hybrid work this fall and beyond, JLL's (NYSE: JLL) Technology and Innovation in the Hybrid Age report finds that tech-enabled solutions are crucial to the success of the hybrid work model.
  • Top technologies in service of hybrid work that are currently in place across companies surveyed include remote working technology (47%), in-office collaboration technology (40%) and workplace experience apps (36%).
  • With 55% of office-based employees now in a hybrid work pattern, companies must increase the rate of technology adoption to meet workforce preferences and business goals.
  • 44% of large organizations are reporting that they are working with external partners to accelerate commercial real estate technology implementation.

Digital Brand Architects Announces Acquisition of Digital Golf Collective

Retrieved on: 
Tuesday, August 30, 2022
Partnership, DBA, Jess, DGC, Golf, Sport, SVP, UTA, DBP, DM, McAlister, United Talent Agency, Acquisition, Rastogi, Growth, Industry, Marketing, Social media, Travel, Public relations, Retail, Creative industries

WEST HOLLYWOOD, Calif., Aug. 30, 2022 /PRNewswire/ -- The leading influencer management company Digital Brand Architects (DBA), a United Talent Agency (UTA) company, announced today that it has acquired golf marketing and digital talent management company, Digital Golf Collective (DGC).

Key Points: 
  • WEST HOLLYWOOD, Calif., Aug. 30, 2022 /PRNewswire/ -- The leading influencer management company Digital Brand Architects (DBA), a United Talent Agency (UTA) company, announced today that it has acquired golf marketing and digital talent management company, Digital Golf Collective (DGC).
  • DBA will leverage its expertise in digital talent management, brand development and extensive resource network to expand upon DGC's existing opportunities and capabilities in digital talent representation, brand marketing, social media management and strategic partnerships within sports and lifestyle.
  • All of DGC's individual digital talent and branding clients, including Tisha Alyn, Ryan Rustand and Cassandra Meyer, will join DBA's roster of leading digital talent.
  • Digital Golf Collective is a minority-owned full-service marketing and talent brand management company focused on the golf industry.

Second Google Vet Joins Suki as VP of Product and Design

Retrieved on: 
Thursday, August 18, 2022
Health, Technology, Practice Management, Health Technology, Software, General Health, Artificial Intelligence, Knowledge, Machine learning, Documentation, CEO, IOS, Algorithm, American Academy, Technology, Joint Innovation Lab, Rastogi, Leadership, School, American Academy of Family Physicians, Gold medal, Human, Institute, Jim Breyer, Twitter, Indian School of Business, SSP, Indian Institutes of Management, AAFP, Android, Google, Gold, Physician, Solution, LinkedIn, Natural language processing, Medicine, Paytm, Management, Venrock

Belwadi Srikanth joins the company as the new vice president of product and design along with Anmol Rastogi, who was named senior director of product management.

Key Points: 
  • Belwadi Srikanth joins the company as the new vice president of product and design along with Anmol Rastogi, who was named senior director of product management.
  • Srikanth joins Suki following more than 15 years with Google, where he was the director of product management, leading innovations in Search, Discovery and Knowledge Graph.
  • Rastogi joins Suki as senior director of product management, bringing over 15 years of experience in product management and software engineering.
  • Prior to Suki, Anmol served as vice president of products with Lendingkart and India product lead with Talaboth Bangalore-based operations.

Unicycive Reports Key Findings from Independent Renal Dietitian Survey

Retrieved on: 
Tuesday, July 26, 2022
Renal osteodystrophy, Osteoporosis, ESRD, Diabetes, Absorption, Kidney disease, Kidney, GLOBE, CKD, Intelligence, Mortality, Acute kidney injury, Dialysis, Cardiovascular disease, Fracture, Compliance, Hyperphosphatemia, Bone pain, Atherosclerosis, Chronic kidney disease, Risk, Therapy, SHPT, Biotechnology, Artery, Company, Gastrointestinal tract, Patient, Nasdaq, Bone disease, Hypertension, Pharmacotherapy, LOS, Lanthanum carbonate, Pharmaceutical industry, Rastogi

LOS ALTOS, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the results from an independent survey of renal dietitians conducted by Spherix Global Insights, an independent business intelligence firm that leverages its own independent data and expertise to provide strategic guidance. The survey canvassed 100 U.S. renal dietitians regarding a variety of topics related to the treatment of their chronic kidney disease and dialysis patients.

Key Points: 
  • The survey canvassed 100 U.S. renal dietitians regarding a variety of topics related to the treatment of their chronic kidney disease and dialysis patients.
  • Key findings from the Spherix survey:
    As renal dietitians indicate they have high influence on brand selection for phosphate binders, the results of this survey are an important barometer that further support the potential for Renazorb to be the phosphate binder of choice, said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive.
  • The Unicycive team is preparing to capitalize on this substantial opportunity by offering patients and providers an attractive treatment alternative.
  • Unicycive is conducting important market research to inform its brand and market access strategy and comprehensive launch plan for Renazorb.

Unicycive Reports Key Findings from Market Research with Nephrologists

Retrieved on: 
Wednesday, July 20, 2022
Renal osteodystrophy, Osteoporosis, ESRD, Diabetes, Trademark, Absorption, Kidney disease, Kidney, GLOBE, CKD, Mortality, Acute kidney injury, U.S. Securities and Exchange Commission, Dialysis, Calcium, Research, Fracture, Cardiovascular disease, Compliance, Hyperphosphatemia, Bone pain, Private Securities Litigation Reform Act, Chronic kidney disease, Atherosclerosis, Risk, Failure, Therapy, Safety, COVID-19, Strategic management, SHPT, Nephrology, Biotechnology, Artery, MBA, FDA, Company, Security (finance), Gastrointestinal tract, Patient, Nasdaq, Bone disease, Coronavirus, Hypertension, Sevelamer, Face, LLC, Pharmacotherapy, LOS, Lanthanum carbonate, Pharmaceutical industry, Genzyme, Rastogi

LOS ALTOS, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the results from a primary market research study conducted on behalf of the company by Reason Research, LLC. The study was a discrete-choice model (“conjoint”) analysis in which 100 US-based nephrologists were presented with various phosphate binder attributes, including efficacy, safety/tolerability, pill burden, composition (calcium or non-calcium based), and dose form (chewable or swallowed), in a trade-off methodology to determine comparative prescribing preferences for currently available phosphate binders and Renazorb®, Unicycive’s product under development.

Key Points: 
  • Key findings from the research:
    Nephrologists estimate that they will prescribe Renazorb (pending FDA approval) for a market-leading 34% of their dialysis patients requiring phosphate binder therapy.
  • This market research with nephrologists, the predominant prescribers of phosphate binders, provides strong validation for our belief in the best-in-class potential of the Renazorb product profile, said Doug Jermasek, MBA, Executive Vice President, Corporate Strategy at Unicycive.
  • These survey results give us further confidence in the significant market opportunity for Renazorb.
  • Unicycive is conducting important market research to inform its brand and market access strategy and comprehensive launch plan for Renazorb.

Unicycive Initiates Pivotal Clinical Bioequivalence Study of Renazorb to Treat Hyperphosphatemia

Retrieved on: 
Thursday, June 2, 2022
Osteoporosis, Absorption, Company, SHPT, Biotechnology, Bone pain, Food, Gastrointestinal tract, Renal osteodystrophy, Artery, Dialysis, Kidney, Hyperphosphatemia, Nasdaq, Chronic kidney disease, Acute kidney injury, Therapy, FDA, Cardiovascular disease, Patient, GLOBE, Pharmacotherapy, Mortality, Risk, Diabetes, Trial of the century, Fracture, Compliance, Kidney disease, Atherosclerosis, Clinical trial, LOS, CKD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Bone disease, Hypertension, ESRD, Pharmaceutical industry, Lanthanum carbonate, Rastogi

LOS ALTOS, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease today announced the initiation of its pivotal clinical bioequivalence (BE) study of Renazorb (lanthanum dioxycarbonate.)

Key Points: 
  • LOS ALTOS, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease today announced the initiation of its pivotal clinical bioequivalence (BE) study of Renazorb (lanthanum dioxycarbonate.)
  • Renazorb is a novel phosphate binding agent utilizing proprietary nanoparticle technology that is being developed by Unicycive for the treatment of hyperphosphatemia.
  • The study is a randomized, open label, two-way crossover BE study to establish pharmacodynamic bioequivalence between Renazorb and Fosrenol.
  • The Renazorb program is supported by a previously completed clinical trial that studied Renazorb in 32 healthy volunteers.